September 12, 2016

MED-C's Groundbreaking NGS Registry Gets IRB Approval
-- Precision Medicine Nonprofit in Position to Become Early Contributor to Cancer Moonshot Initiative --

    WASHINGTON, DC, September 12, 2016 /24-7PressRelease/ -- The White House Cancer Moonshot has challenged medicine to speed progress in battling America's No. 2 killer. A nonprofit upstart soon will start making significant contributions toward this goal after approval of its study this week by a national institutional review board (IRB).

This approval will allow the Molecular Evidence Development Consortium (MED-C) to launch its N1 Registry, expected to become the largest and most complete openly available cancer database including next-generation sequencing (NGS) data accompanied by clinical outcomes.

"With IRB approval we can proceed to take the final steps toward launching the N1 Registry," said Dr. Dane J. Dickson, M.D., and CEO of MED-C. "We are confident our efforts will contribute significantly to the Moonshot's challenges to enhance data sharing and improve clinical trials processes."

MED-C's registry will be overseen by an investigator core of 15 internationally recognized hematology and oncology leaders and closely monitored by key industry organizations as a potential disruptive innovation in precision medicine.

A summary of the protocol is recorded on, entitled "Patients Diagnosed with Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A MED-C Observational Registry (N1)"

MED-C is a nonprofit organization aiming to unify all key medical stakeholders to advance precision medicine through its N1 Registry that will contain standardized, high-quality, next-generation sequencing combined with clinical outcomes.

# # #

Contact Information:
Lee Warnick
Molecular Evidence Development Consortium (MED-C)
Washington, DC
Voice: 208-206-7516

If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Use disclaimer for more information.
This News Release can be viewed online at: